Thromboembolism Global Clinical Trials Review, H2, 2016

GlobalData
349 Pages - GLDATA58532
$2,500.00

Summary

GlobalData's clinical trial report, “Thromboembolism Global Clinical Trials Review, H2, 2016" provides an overview of Thromboembolism clinical trials scenario. This report provides top line data relating to the clinical trials on Thromboembolism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies Mentioned

C. H. Boehringer Sohn AG & Co. KG
Bayer AG
Bristol-Myers Squibb Company
Sanofi
Pfizer Inc
GlaxoSmithKline Plc
Astellas Pharma Inc
Daiichi Sankyo Company Ltd
Johnson & Johnson
AstraZeneca Plc

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Thromboembolism to Cardiovascular Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Thromboembolism to Cardiovascular Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Thromboembolism Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Thromboembolism 29
Nov 07, 2016: Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016 29
Aug 23, 2016: Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016 30
Clinical Trial Profile Snapshots 32
Appendix 346
Abbreviations 346
Definitions 346
Research Methodology 347
Secondary Research 347
About GlobalData 348
Contact Us 348
Disclaimer 348
Source 349

List of Tables
Thromboembolism Therapeutics, Global, Clinical Trials by Region, 2016* 6
Thromboembolism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Thromboembolism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Thromboembolism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Thromboembolism Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Thromboembolism Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Thromboembolism Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Thromboembolism Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Thromboembolism to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 14
Thromboembolism Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Thromboembolism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Thromboembolism to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 17
Thromboembolism Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Thromboembolism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Thromboembolism Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Thromboembolism Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Thromboembolism Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Thromboembolism Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Thromboembolism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Thromboembolism Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Thromboembolism Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Thromboembolism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Thromboembolism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Thromboembolism Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Thromboembolism Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Thromboembolism Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Thromboembolism Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Thromboembolism Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Thromboembolism Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Thromboembolism Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Thromboembolism Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Thromboembolism to Cardiovascular Clinical Trials, G7 Countries (%), 2016* 14
Thromboembolism Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Thromboembolism Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Thromboembolism to Cardiovascular Clinical Trials, E7 Countries (%), 2016* 17
Thromboembolism Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Thromboembolism Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Thromboembolism Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Thromboembolism Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Thromboembolism Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Thromboembolism Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Thromboembolism Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Thromboembolism Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Thromboembolism Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Thromboembolism Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Thromboembolism Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 347

$2,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838



Browse All Reports